Source: Interface Biologics Inc (IBI).
Endexo anti thrombosis additive technology can be used with a range of base polymers.
AngioDynamics, a leading USA-based provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, and Interface Biologics Inc (IBI), a Canadian privately-held commercial stage developer of transformative biomedical-polymer products, have announced that AngioDynamics's exclusive Endexo technology licensing agreement for peripherally inserted catheters (PICCs), ports and dialysis catheters, now includes central venous catheters (CVCs).
Endexo technology is a permanent, non-eluting integral polymer that imparts devices with a passive character demonstrated to have such benefits as reduced platelet and reduced thrombus accumulation on medical devices based on in vitro testing. In contrast to thrombus-resistant coatings or impregnated alternatives, which may be superficial and/or transient, Endexo is incorporated directly into the base polymer to create a material that provides long-term utility and durability without impacting the base underlying mechanical properties of the medical device. The Endexo technology also has significant manufacturing advantages over noted thrombus resistant alternatives as it can be incorporated directly into existing manufacturing processes.
AngioDynamics's BioFlo PICCs with Endexo technology received US FDA clearance in September 2012, and it is similarly approved in Europe and Canada. In August, the Company's BioFlo Port with Endexo technology also received FDA clearance.
"We are pleased to build on our BioFlo platform's success by extending our agreement with Interface Biologics to include CVCs," said Chuck Greiner, Senior Vice President of AngioDynamics's Global Vascular Access Franchise. "We see opportunity in the US$420 mn CVC market, and similar to our other vascular access products, a strong trend toward healthcare solutions that provide protection vs thrombus and infection. The development of a BioFlo CVC with Endexo is consistent with our plan to bring disruptive technologies into the Vascular Access space, allowing us to offer more options to customers and improve our position with GPOs/IDNs."
"We have developed a strong working relationship with AngioDynamics during the last few years and are excited about the BioFlo PICC's reported clinical benefits and resultant commercial traction," said Tom Reeves, President and CEO of Interface Biologics "Extending our agreement to include CVCs exemplifies both our commitment to AngioDynamics and their confidence in the ability of our Endexo additives to improve the safety and efficacy of their products."